| 1 |
中华医学会呼吸病学分会哮喘学组，中国哮喘联盟. 重症哮喘诊断与处理中国专家共识[J].中华结核和呼吸杂志, 2017, 40(11):813-829.
|
| 2 |
Shrimanker R. Interleukin-5 inhibitors for severe asthma: rationale and future outlook [J]. BioDrugs, 2017, 31(2):93-103.
|
| 3 |
Chung KF, Wenzel SE, Brozek JL, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma [J]. Eur Respir J, 2014, 43(2):343-373.
|
| 4 |
Haasler I.Biologicals in the treatment of bronchial asthma [J]. Pneumologie, 2017, 71(10):684-698.
|
| 5 |
Koike M, Nakamura K, Furuya A, et al. Establishment of humanized anti-interleukin-5 receptor alpha chain monoclonal antibodies having a potent neutralizing activity [J]. Hum antibodies, 2009, 18(1-2):17-27.
|
| 6 |
Ghazi A, Trikha A, Calhoun WJ. Benralizumab-a humanized mAb to IL-5Rα with enhanced antibody-dependent cell-mediated cytotoxicity-a novel approach for the treatment of asthma [J]. Expert opini Biol Ther, 2012, 12(1):113-118.
|
| 7 |
Tavernier J, Devos R, Cornelis S, et al. A human high affinity interleukin-5 receptor (IL5R) is composed of an IL5-specific alpha chain and a beta chain shared with the receptor for GM-CSF [J]. Cell, 1991, 66(6):1175-1184.
|
| 8 |
Koike M, Nakamura K, Furuya A, et al. Establishment of humanized anti-interleukin-5 receptor alpha chain monoclonal antibodies having a potent neutralizing activity [J]. Hum Antibodies, 2009, 18(1-2):17-27.
|
| 9 |
Busse WW, Katial R, Gossage D, et al.Safety profile, pharmacokinetics, and biologic activity of MEDI-563, an anti-IL-5 receptor alpha antibody, in a phaseⅠ study of subjects with mild asthma [J]. J Allergy Clin Immunol, 2010, 125(6):1237-1244.
|
| 10 |
Saco TV, Pepper AN, Lockey RF. Benralizumab for the treatment of asthma [J]. Expert Rev Clin Immunol, 2017, 13(5):405-413.
|
| 11 |
Shields RL, Lai J, Keck R, et al. Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fcgamma RIII and antibody-dependent cellular toxicity [J]. J Biol Chem, 2002, 277(30):26733-26740.
|
| 12 |
Matera MG, Calzetta L, Rinaldi B, et al. Pharmacokinetic/pharmacodynamic drug evaluation of benralizumab for the treatment of asthma [J]. Expert opin Drug Metab Toxicol, 2017, 13(9):1007-1013.
|
| 13 |
Kaufman MB. Pharmaceutical approval update [J]. P T, 2018, 43(1):22-60.
|
| 14 |
Kolbeck R, Kozhich A, Koike M, et al. MEDI-563, a humanized anti-IL-5 receptor alpha mAb with enhanced antibody-dependent cell-mediated cytotoxicity function [J]. J Allergy Clin Immunol, 2010, 125(6):1344-1353.
|
| 15 |
Laviolette M, Gossage DL, Gauvreau G, et al. Effects of benralizumab on airway eosinophils in asthmatic patients with sputum eosinophilia [J]. J Allergy Clin Immunol, 2013, 132(5):1086-1096.
|
| 16 |
Khorasanizadeh M, Eskian M, Rezaei N. Reductions in eosinophil biomarkers by benralizumab in patients with asthma [J]. Acta Med Iran, 2017, 55(5):352-353.
|
| 17 |
Nowak RM, Parker JM, Silverman RA, et al.A randomized trial of benralizumab, an antiinterleukin 5 receptor α monoclonal antibody, after acute asthma [J]. Am J Emerg Med, 2015, 33(1):14-20.
|
| 18 |
Bleecker ER, FitzGerald JM, Chanez P, et al.Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial [J]. Lancet, 2016, 388(10056):2115-2127.
|
| 19 |
FitzGerald JM, Bleecker ER, Nair P, et al.Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial [J]. Lancet, 2016, 388(10056):2128-2141.
|
| 20 |
Nair P, Wenzel S, Rabe KF, et al. Oral glucocorticoid-sparing effect of benralizumab in severe asthma [J]. N Engl J Med, 2017, 376(25):2448-2458.
|
| 21 |
Antoniu SA. Benralizumab as a potential treatment of asthma [J]. Expert Opin Biol Ther, 2017, 17(7):895-900.
|
| 22 |
Tian BP, Zhang GS, Lou J, et al. Efficacy and safety of benralizumab for eosinophilic asthma: A systematic review and meta-analysis of randomized controlled trials [J]. J Asthma, Epub 2017 Dec 6:1-10.
|
| 23 |
Matera MG, Calzetta L,Rinaldi B, et al.Pharmacokinetic/pharmacodynamic drug evaluation of benralizumab for the treatment of asthma [J]. Expert Opin Drug Metab Toxicol, 2017, 13(9):1007-1013.
|